Boston Scientific: from profit to three straight losses.
- Industry
- Surgical & Medical Instruments & Apparatus
- Headquarters
- United States
- Ticker
- BSX (NYSE)
- Sources
- SEC filings (1995–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
- Data as of
- November 15, 2026
- From profit to three straight losses. Boston Scientific lost money every year from 2013 to 2015: $0.5 billion in all. 2016 was its first profit in four years: $0.3 billion.
- Leaders came and went. Boston Scientific filed 39 leadership changes since 2016, more than 91% of large manufacturers (the median is 20). The day after each, its shares fell a median 0.5 points against its sector.
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $9.1 billion | $0.3 billion | |
| 2017 | $9 billion | $0.1 billion | |
| 2018 | $9.8 billion | $1.7 billion | |
| 2019 | $10.7 billion | $4.7 billion | |
| 2020 | $9.9 billion | −$0.1 billion | |
| 2021 | $11.9 billion | $1 billion | |
| 2022 | $12.7 billion | $0.7 billion | |
| 2023 | $14.2 billion | $1.6 billion | |
| 2024 | $16.7 billion | $1.8 billion | |
| 2025 | $20.1 billion | $2.9 billion |
As reported in its annual filings. Losses in red.
Has Boston Scientific had layoffs?
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | approximately 48,000 | December 31, 2023 |
| 10-K for 2024 | approximately 53,000 | December 31, 2024 |
| 10-K for 2025 | approximately 59,000 | December 31, 2025 |
Job cuts, severance and restructuring
Board approved a new global restructuring program, the 2023 Restructuring Plan, with expected limited role reductions and a total estimated pre-tax charge range.
“The 2023 Restructuring Plan is expected to result in 23 total pre-tax charges of approximately $450 million to $550 million and reduce gross annual pre-tax expenses by approximately $225 million to $275 million as program benefits are realized.” 10-K for 2023
Company recorded restructuring charges under the 2023 Restructuring Plan, plus restructuring-related charges, in 2023.
“Pursuant to the 2023 Restructuring Plan, we recorded restructuring charges in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 420, Exit or Disposal Cost Obligations of $69 million in 2023.” 10-K for 2023
Company expects termination benefits and other charges under the 2023 Restructuring Plan, with costs for employee-related actions estimated by type.
“Termination benefits (1) $60 - $80 Other (2) 20 - 40 Restructuring-related expenses: Transfer costs (3) 300 - 330 Other (4) 70 - 100 $450 - $550 (1) Plans detailing specific employee impacts will be developed for each affected region and business, working with employee representative bodies where required under local laws.” 10-K for 2023
Company reported cash outlays expected from the 2023 Restructuring Plan.
“The implementation of the 2023 Restructuring Plan is estimated to result in total pre-tax charges of approximately $450 million to $550 million, of which approximately $350 million to $450 million is expected to result in cash outlays, and reduce gross annual pre-tax expenses by approximately $225 million to $275 million as program benefits are realized.” 10-K for 2023
Company completed its 2019 Restructuring Plan, reporting its total charges and cash outlays, and recorded 2022 charges under it.
“The 2019 Restructuring Plan resulted in total pre-tax charges of $461 million and approximately $404 million in cash outlays.” 10-K for 2023
The company recorded restructuring charges and restructuring-related charges under the 2023 Restructuring Plan during 2024.
“We recorded Restructuring net charges (credits) of $ 16 million in 2024, $ 69 million in 2023 and $ 24 million in 2022.” 10-K for 2024
The company reported a restructuring reserve balance at year end, reflecting severance and other exit costs not yet paid.
“The restructuring reserve balance as of December 31, 2024 and 2023 was $ 26 million and $ 41 million, respectively.” 10-K for 2024
The 2023 Restructuring Plan includes termination benefits for affected employees, with plans developed by region and business.
“Plans detailing specific employee impacts will be developed for each affected region and business, working with employee representative bodies where required under local laws.” 10-K for 2024
The company committed to a global restructuring program in February 2023 to simplify its manufacturing and distribution network and expand operating efficiencies.
“The 2023 Restructuring Plan is expected to result in total pre-tax charges of approximately $700 million to $800 million and reduce gross annual pre-tax expenses by approximately $350 million to $400 million as program benefits are realized.” 10-K for 2025
The Board approved expanding the 2023 Restructuring Plan with up to $250 million in additional pre-tax charges for further efficiency and functional optimization activities.
“On July 29, 2025, our Board of Directors approved expanding the 2023 Restructuring Plan by up to $250 million in aggregate additional pre-tax charges, to include further related activities under the program to drive operational efficiencies and optimize functional capabilities.” 10-K for 2025
The company discontinued worldwide sales of the ACURATE aortic valve systems and recorded restructuring charges as a result.
“The decision resulted in total pre-tax restructuring and restructuring-related net charges of approximately $87 million in 2025.” 10-K for 2025
| Fiscal year ended | Restructuring charges | Restructuring costs incurred | Cash paid for restructuring |
|---|---|---|---|
| 2016-12-31 | $28 million | $78 million | $82 million |
| 2017-12-31 | $37 million | $95 million | $70 million |
| 2018-12-31 | $36 million | $96 million | — |
| 2019-12-31 | $38 million | — | $64 million |
| 2020-12-31 | $52 million | — | — |
| 2021-12-31 | $40 million | — | — |
| 2022-12-31 | $24 million | — | — |
| 2023-12-31 | $69 million | — | — |
| 2024-12-31 | $16 million | — | — |
| 2025-12-31 | $101 million | — | — |
Boston Scientific filed 5 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
What has Boston Scientific acquired?
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Apollo Endosurgery, Inc.“In the second quarter of 2023, we completed the acquisition of Apollo Endosurgery, Inc., a public company that has developed and commercialized endoscopic suturing devices including OverStitch™ Endoscopic Suturing Systems and X-Tack™ Endoscopic HeliX Tacking Systems and endobariatric devices including the Apollo ESG™ and Apollo REVISE™ Systems, the first devices authorized by the FDA for endoscopic sleeve gastroplasty and endoscopic bariatric revision procedures, as well as the Orbera™ ® Intragastric Balloon for endoscopic weight management.” 10-K for 2023 | acquisition | In the second quarter of 2023 | — |
Relievant Medsystems, Inc.“In addition, in the fourth quarter of 2023, we completed the acquisition of Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept™ Intraosseous Nerve Ablation System, the only FDA-cleared system to treat vertebrogenic pain, a form of chronic low back pain.” 10-K for 2023 | acquisition | In the fourth quarter of 2023 | — |
Acotec Scientific Holdings Limited (majority stake)“In the first quarter of 2023, we acquired a majority stake investment in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons and other products used in the treatment of vascular and other diseases, complementing our existing Peripheral Interventions portfolio.” 10-K for 2023 | acquisition | In the first quarter of 2023 | — |
Axonics, Inc.“On January 8, 2024, we announced our entry into a definitive agreement to acquire Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction.” 10-K for 2023 | agreed acquisition | — | — |
pathology business“as well as the divestiture of our pathology business during the second quarter of 2023 and our acquisition of Baylis Medical Company Inc. (Baylis Medical) during the first quarter of 2022, for which there is less than a full period of comparable net sales.” 10-K for 2023 | divestiture | during the second quarter of 2023 | — |
Axonics, Inc. (Axonics)“In the fourth quarter of 2024, we completed the acquisition of Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction.” 10-K for 2024 | acquisition | In the fourth quarter of 2024 | — |
Silk Road Medical, Inc. (Silk Road Medical)“In the third quarter of 2024, we completed our acquisition of Silk Road Medical, Inc. (Silk Road Medical), a publicly traded medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally-invasive procedure called transcarotid artery revascularization.” 10-K for 2024 | acquisition | In the third quarter of 2024 | — |
endoluminal vacuum therapy portfolio of B. Braun Medical Inc.“Operational net sales growth included organic net sales growth of 8.0 percent in 2024, and the positive impact of 100 basis points from our acquisition of Apollo and the divestiture of our pathology business in the second quarter of 2023, and our acquisition of the endoluminal vacuum therapy portfolio of Braun in the first quarter of 2024.” 10-K for 2024 | acquisition | first quarter of 2024 | — |
Acotec Scientific Holdings Limited (Acotec)“In 2023, relevant acquisitions and divestitures included our majority stake investment in Acotec Scientific Holdings Limited (Acotec) and the acquisitions of Apollo Endosurgery, Inc. (Apollo) and Relievant Medsystems, Inc. (Relievant) during the first, second and fourth quarters of 2023, respectively, as well as the divestiture of our pathology business during the second quarter of 2023.” 10-K for 2024 | acquisition | — | — |
Apollo Endosurgery, Inc. (Apollo)“In 2023, relevant acquisitions and divestitures included our majority stake investment in Acotec Scientific Holdings Limited (Acotec) and the acquisitions of Apollo Endosurgery, Inc. (Apollo) and Relievant Medsystems, Inc. (Relievant) during the first, second and fourth quarters of 2023, respectively, as well as the divestiture of our pathology business during the second quarter of 2023.” 10-K for 2024 | acquisition | — | — |
Relievant Medsystems, Inc. (Relievant)“Operational net sales growth included organic net sales growth of 2.7 percent in 2024, and the positive impact of 1,100 basis points from our acquisition of Relievant in the fourth quarter of 2023.” 10-K for 2024 | acquisition | fourth quarter of 2023 | — |
Cryterion Medical, Inc. (Cryterion)“The impairment charges recorded in 2024 were primarily associated with amortizable intangible assets established in connection with our acquisitions of Cryterion Medical, Inc. (Cryterion) and Devoro Medical, Inc. (Devoro), which were integrated into our Electrophysiology and Peripheral Interventions business units, respectively.” 10-K for 2024 | acquisition | — | — |
Devoro Medical, Inc. (Devoro)“The impairment charges recorded in 2024 were primarily associated with amortizable intangible assets established in connection with our acquisitions of Cryterion Medical, Inc. (Cryterion) and Devoro Medical, Inc. (Devoro), which were integrated into our Electrophysiology and Peripheral Interventions business units, respectively.” 10-K for 2024 | acquisition | — | — |
Bolt Medical, Inc.“In the second quarter of 2025, we completed our acquisition of the remaining shares of Bolt Medical, Inc. (Bolt Medical), the developer of an intravascular lithotripsy advanced laser-based platform for the treatment of coronary and peripheral artery disease.” 10-K for 2025 | acquisition | In the second quarter of 2025 | — |
SoniVie Ltd.“In addition, we completed the acquisition of the remaining shares of SoniVie Ltd. (SoniVie), a privately held medical device company that has developed the TIVUS™ Intravascular Ultrasound System.” 10-K for 2025 | acquisition | — | — |
Penumbra, Inc.“The definitive agreement, entered into on January 15, 2026, to acquire Penumbra, for approximately $14.500 billion, which is expected to close during 2026, subject to customary closing conditions.” 10-K for 2025 | agreed acquisition | January 15, 2026 | approximately $14.500 billion |
Nalu Medical, Inc.“On January 27, 2026, we completed our acquisition of 100 percent of Nalu Medical, Inc. (Nalu Medical), a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic pain.” 10-K for 2025 | acquisition | January 27, 2026 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2016-12-31 | $408 million | — | $208 million |
| 2017-12-31 | $560 million | — | $308 million |
| 2018-12-31 | $1.45 billion | $0 | $942 million |
| 2019-12-31 | $4.38 billion | $90 million | $2.22 billion |
| 2020-12-31 | $3 million | $15 million | — |
| 2021-12-31 | $2.26 billion | $826 million | $2.06 billion |
| 2022-12-31 | $1.54 billion | $5 million | $1.03 billion |
| 2023-12-31 | $1.81 billion | $0 | $1.45 billion |
| 2024-12-31 | $4.64 billion | $0 | $2.79 billion |
| 2025-12-31 | $1.59 billion | — | $1.06 billion |
Deal filings since 2016
- 2026-02-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-01-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-02-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-02-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-01-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-03-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-05-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-04-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-02-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-12-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-11-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-02-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-12-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-11-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-08-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-02-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-08-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-02-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Who are Boston Scientific's competitors?
Who Boston Scientific names
Boston Scientific’s annual reports for 2023 to 2025 describe its competition by kind of business and do not name competing companies.
Who names Boston Scientific
Companies whose own annual reports name Boston Scientific as a competitor.
“In addition, there are a number of companies, including Cardiovascular Systems Inc., Abbott Laboratories, Medtronic, Edwards Lifesciences, Boston Scientific, LivaNova, Terumo Heart, Teleflex, Getinge (Maquet Cardiovascular) and several early-stage companies, that are developing medical devices that provide circulatory support and oxygenation, including implantable left ventricular assist devices, miniaturized rotary ventricular assist devices and cardiopulmonary bypass devices that directly and indirectly compete with our products.” 10-K for 2022
“On a product basis, our principal competitors are Steris, Olympus, Boston Scientific, ASP (a division of Fortiv), Metrex, Ruhof, Ecolab, ERBE, Getinge, SteelCo and Wassenburg.” 10-K for 2020
“Alphatec Holdings, Orthofix, Integra LifeSciences , ZimVie, VB Spine, Boston Scientific and other smaller public and private companies are also competitors of ours.” 10-K for 2025
“Competitors such as Abbott Laboratories, Boston Scientific, and Philips pose challenges and opportunities in the coronary physiology segment, each offering their own technologies and solutions.” 10-K for 2026
“Our primary competitors in our peripheral intervention market are Teleflex Incorporated (“Teleflex”), Cook Medical Incorporated (“Cook Medical”), Medtronic plc (“Medtronic”), Boston Scientific Corporation (“Boston Scientific”), and Becton, Dickinson and Company (“BD”).” 10-K for 2025
“Our most notable competitors are Boston Scientific, Medtronic, Stryker (now including Inari Medical), Terumo and several private companies.” 10-K for 2025
“On a product basis, competitors include 3M, Baxter, Boston Scientific, Belimed, Ecolab, Fortive, Getinge, Karl Storz, Olympus, Ruhof, SteelCo, Stryker, Skytron and Wassenburg.” 10-K for 2026
“Our primary competitors include: Boston Scientific Corporation; Cook Medical LLC; Medtronic plc; Merit Medical Systems, Inc.; Terumo Medical Corporation; AngioDynamics, Inc.; MedWaves, Inc.; and Johnson & Johnson.” 10-K for 2020
What are Boston Scientific's subsidiaries?
Subsidiaries it lists
| Subsidiary | Jurisdiction |
|---|---|
| Ablacon GmbH | Germany |
| Ablacon SA, en liquidation | Switzerland |
| Acotec Scientific Holdings Limited | Cayman Islands |
| Acurate Industria e Comercio Ltda. | Brazil |
| American Medical Systems Europe B.V. | The Netherlands |
| Anchors (HZ) Medical Technology Co., Ltd. | China |
| Anrei Medical Device (Hangzhou) Co., Ltd. | China |
| Anrei Medical Device (Tianjin) Co., Ltd. | China |
| Apollo Endosurgery UK Ltd | England |
| Apollo Endosurgery US, Inc. | Delaware |
| Apollo Endosurgery, Inc. | Delaware |
| Axonics, Inc. | Delaware |
| Axonics Modulation Technologies Australia Pty Ltd | Australia |
| Axonics Modulation Technologies, U.K. Limited | England |
| Axonics Women’s Health Limited | England |
| Baylis Medical Company Inc. | Canada |
| Baylis Medical USA Inc. | Delaware |
| Biocompatibles UK Limited | England |
| Biocompatibles, Inc. | Delaware |
| Bolt Medical, Inc. | Delaware |
| Boston Scientific (Malaysia) Sdn. Bhd. | Malaysia |
| Boston Scientific (South Africa) Proprietary Limited | South Africa |
| Boston Scientific (Thailand) Ltd. | Thailand |
| Boston Scientific AG | Switzerland |
| Boston Scientific Argentina S.A. | Argentina |
| Boston Scientific Asia Pacific Pte. Ltd. | Singapore |
| Boston Scientific Benelux NV | Belgium |
| Boston Scientific Cardiac Diagnostic Services, LLC | Delaware |
| Boston Scientific Cardiac Diagnostic Technologies, Inc. | Delaware |
| Boston Scientific Cardiac Diagnostics, Inc. | Delaware |
| Boston Scientific Ceska republika s.r.o. | Czech Republic |
| Boston Scientific Chile SpA | Chile |
| Boston Scientific Clonmel Limited, in liquidation | Ireland |
| Boston Scientific Colombia Limitada | Colombia |
| Boston Scientific Comercial de Costa Rica BSCR, S.R.L. | Costa Rica |
| Boston Scientific de Costa Rica S.R.L. | Costa Rica |
| Boston Scientific de Mexico, S.A. de C.V. | Mexico |
| Boston Scientific del Caribe, Inc. | Puerto Rico |
| Boston Scientific do Brasil Ltda. | Brazil |
| Boston Scientific Egypt LLC | Egypt |
| Boston Scientific Far East B.V. | The Netherlands |
| Boston Scientific Gesellschaft m.b.H. | Austria |
| Boston Scientific Group Limited | Ireland |
| Boston Scientific Gulf for Trading | Saudi Arabia |
| Boston Scientific Healthcare Technology (Shanghai) Co., Ltd. | China |
| Boston Scientific Hellas S.A. | Greece |
| Boston Scientific Holding One B.V. | The Netherlands |
| Boston Scientific Holding Two B.V. | The Netherlands |
| Boston Scientific Hong Kong Limited | Hong Kong |
| Boston Scientific Iberica, S.A. | Spain |
| Boston Scientific India Private Limited | India |
| Boston Scientific International B.V. | The Netherlands |
| Boston Scientific International Distribution FZE | UAE |
| Boston Scientific International Finance Limited | Ireland |
| Boston Scientific International LLC | Delaware |
| Boston Scientific International S.A. | France |
| Boston Scientific International Sdn. Bhd. | Malaysia |
| Boston Scientific Israel Ltd. | Israel |
| Boston Scientific Japan K.K. | Japan |
| Boston Scientific Korea Co., Ltd. | Korea |
| Boston Scientific Korea Holding Co., Ltd. | Korea |
| Boston Scientific Limited | England |
| Boston Scientific Limited | Ireland |
| Boston Scientific LLC | Russian Federation |
| Boston Scientific Ltd./Boston Scientifique Ltee. | Canada |
| Boston Scientific Medical Device Limited | Ireland |
| Boston Scientific Medical Device (Malaysia) Sdn. Bhd. | Malaysia |
| Boston Scientific Medical Technology (Shanghai) Co., Ltd. | China |
| Boston Scientific Medizintechnik GmbH | Germany |
| Boston Scientific Middle East FZ-LLC | UAE |
| Boston Scientific Middle East SAL (Offshore) | Lebanon |
| Boston Scientific Nederland B.V. | The Netherlands |
| Boston Scientific Neuromodulation Corporation | Delaware |
| Boston Scientific New Zealand Limited | New Zealand |
| Boston Scientific Nordic AB | Sweden |
| Boston Scientific Pakistan (Private) Limited | Pakistan |
| Boston Scientific Peru S.A.C. | Peru |
| Boston Scientific Philippines, Inc. | Philippines |
| Boston Scientific Polska Sp. z o.o. | Poland |
| Boston Scientific Portugal - Dispositivos Medicos, Lda | Portugal |
| Boston Scientific Pty Ltd | Australia |
| Boston Scientific Puerto Rico LLC | Puerto Rico |
| Boston Scientific Regional Headquarters | Saudi Arabia |
| Boston Scientific Romania S.R.L. | Romania |
| Boston Scientific S.A.S. | France |
| Boston Scientific S.p.A. | Italy |
| Boston Scientific Scimed, Inc. | Minnesota |
| Boston Scientific Technology & Engineering Services Private Limited | India |
| Boston Scientific TIP Gerecleri Limited Sirketi | Turkey |
| Boston Scientific Vietnam Company Limited | Vietnam |
| BSC International Medical Trading (Shanghai) Co., Ltd. | China |
| BSC Medical Device Technology (Shanghai) Co., Ltd. | China |
| BTG IM Holdings Ltd., in liquidation | Israel |
| BTG International Canada Inc. | Canada |
| BTG International Limited | England |
| BTG Limited | England |
| Cardiac Pacemakers, Inc. | Minnesota |
| CarioICE LLC | Delaware |
| Chess Medical Inc. | Canada |
| Corbin Clinical Resources, Inc. | Delaware |
| Corbin Clinical Resources, LLC | Maryland |
| Cortex, Inc. | Delaware |
| DeVoro Medical Inc. | Delaware |
| eCardio Sequoia Blocker Corp. | Delaware |
| Electron Acquisition Corporation | Delaware |
| EndoChoice, Inc. | Delaware |
| EP Technologies, Inc. | Delaware |
| Falcon Merger Sub, Inc. | Delaware |
| Farapulse, Inc. | Delaware |
| Galil Medical Inc. | Delaware |
| Galil Medical Ltd., in liquidation | Israel |
| Golden Woods Services, LLC | Texas |
| Guidant Delaware Holding Corporation | Delaware |
| Guidant Europe NV | Belgium |
| Iceberg Merger Sub, Inc. | Delaware |
| Intera Oncology Inc. | Delaware |
| JND Therapeutics, Inc. | Delaware |
| Laguna Holdco Ltd. | Israel |
| Lumenis (HK) Limited | Hong Kong |
| Lumenis India Private Limited | India |
| Lumenis Ltd. | Israel |
| Nalu Medical, Inc. | Delaware |
| Notebook Merger Sub, Ltd. | Delaware |
| NXT Merger Corp. | Delaware |
| Obsidio, Inc. | Delaware |
| Pinehurst Merger Sub, Inc. | Delaware |
| Provensis Limited | England |
| PT Boston Scientific Indonesia | Indonesia |
| Relievant Medsystems, Inc. | Delaware |
| RMI Acquisition Corp. | California |
| Shanghai Anzhiqiao Medical Technology Co., Ltd. | China |
| Silk Road Medical, Inc. | Delaware |
| SNS Merger Corp. | Delaware |
| SoniVie Ltd. | Israel |
| SoniVie, Inc. | Delaware |
| SoundCath, Inc. | Delaware |
| Special K Merger Corp. | Delaware |
| Stream Enterprises LLC | Delaware |
| Symetis SA, en liquidation | Switzerland |
| Target Therapeutics, Inc. | Delaware |
| VBio Merger Subsidiary, Inc. | Delaware |
| VTC Merger Subsidiary, Inc. | Delaware |
| Zuma Investment Pty Ltd | Australia |
| 165Bio Inc. | Delaware |
| 34 Biomedical Merger Corp. | Delaware |
| 9357-1867 Quebec Inc., d/b/a Cryterion Medical Enterprise | Canada |
From Exhibit 21 of the 10-K for 2025. Companies must list their significant subsidiaries there and may leave out smaller ones, so this is the company’s own list, not every entity it owns.
Layoffs, acquisitions, competitors and subsidiaries are read from Boston Scientific’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023), as of 2026-02-17.
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 69 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (44 with market data).
- Economic context: 7 measures for the United States, every year since 2016, from the official sources.
- Peer comparison: against 264 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.
Tools to try
- Ansoff move finderFramework: Ansoff Matrix
- Business model canvas builderFramework: Business Model Canvas
- Change readiness checkFramework: Kotter's 8-Step Change Model
- Five Forces scorerFramework: Porter's Five Forces
- SMART goal builderFramework: SMART Goals
- SWOT builderFramework: SWOT Analysis
More from Stratrix
The Business Model Wizard
Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.
Free · about twelve minutesBuild your Model Thesis →Test a decision, free
Set a live decision against the companies that made it before you.
AcquisitionsThe Distance TestDivestituresThe Divestiture TestDiversificationThe Diversification TestMake or buyThe Make-or-Buy TestWeekly email
Stratonomics, every Tuesday
One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.